He currently serves as the senior vice president of research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.
Manning is responsible for research and the discovery of novel products as the senior vice president of research at Momenta Pharmaceuticals, Inc.
Since joining Momenta, his team has advanced three novel autoimmune drugs into development.
Prior to Momenta, Manning was vice president and head of immunology research for Biogen Idec, Inc.
Before that, he was vice president and global head of inflammation, autoimmunity and transplantation research at Roche Pharmaceuticals.
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca